Precision
Cell-free DNA Platform
for Millions

So more people get an answer in time to act.

FEATURED UPDATES

Explore our
cfDNA solutions

A small blood sample can reveal a world of information

Cell-free DNA, or cfDNA, consists of tiny fragments of DNA released into the bloodstream as cells naturally renew. These fragments carry biological signals from different parts of the body, offering a unique window into what is happening inside us.

By analyzing the amount, sequence, patterns, and physical characteristics of cfDNA, healthcare professionals can uncover important health insights, sometimes before changes become visible through symptoms or medical imaging.

At Gene Solutions, we transform these tiny signals into meaningful insights across prenatal healthcare, cancer screening, and precision oncology, helping people and their doctors make informed decisions sooner.

Learn how Gene Solutions applies the power of cfDNA across every stage of life and care

PRENATAL HEALTHCARE PLATFORM

triSure

Comprehensive prenatal screening for selected fetal genetic conditions and maternal health risks, from just 10 mL of maternal blood.

CANCER SCREENING PLATFORM

Spot-mas

The clinically validated multi-cancer early detection (MCED) test powered by multi-omics.

PRECISION ONCOLOGY PLATFORM

K-Track / K-4Care

World-class genomic profiling and cancer monitoring powered by multi-omics.

Discover Our AI

& Data Engine

Advancing the frontiers of cell-free DNA

DNAsphere.AI is the data and artificial intelligence engine powering Gene Solutions’ precision cell-free DNA platform, transforming vast multi-omic datasets into biological insights and scalable applications for clinicians and patients worldwide.

Data at Scale

More than 300,000 multi-omic cell-free DNA profiles provide a growing foundation for research and innovation across early cancer detection, precision oncology and reproductive health.

Multimodal Intelligence

Advanced machine-learning and deep-learning models analyze multiple dimensions of cell-free DNA, including genomic, epigenomic and fragmentomic features, to identify patterns that may not be visible through individual signals alone.

From Discovery to Application

DNAsphere.AI helps translate data into new biological insights and scalable applications, from investigating early cancer-associated fragmentomic changes to identifying pregnancy-related risks patterns, enabling efficient, transferable and clinically relevant cfDNA solutions.

News & Insights

Stay connected with our latest global developments, scientific advances, publication highlights, and insights shaping the future of precision cell-free DNA.​

Latest news

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

14 Oct 2026

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind […]

Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

25 Sep 2026

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to […]

Gene Solutions Study in AJOG Global Reports Shows Routine NIPT Data May Help Predict First-Trimester Preterm Birth Risk

24 Sep 2026

Preterm birth (PTB), defined as delivery before 37 completed weeks of gestation, remains one of the most consequential and difficult-to-predict complications in obstetric care. It affects roughly 11% of live births globally and is the leading cause of mortality in children under five years of age. Despite this impact, clinicians still struggle to identify many […]

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

14 Oct 2026

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind […]

Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

25 Sep 2026

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to […]

Gene Solutions Study in AJOG Global Reports Shows Routine NIPT Data May Help Predict First-Trimester Preterm Birth Risk

24 Sep 2026

Preterm birth (PTB), defined as delivery before 37 completed weeks of gestation, remains one of the most consequential and difficult-to-predict complications in obstetric care. It affects roughly 11% of live births globally and is the leading cause of mortality in children under five years of age. Despite this impact, clinicians still struggle to identify many […]

ESMO Congress 2026: Gene Solutions to Present AI-Enabled Multi-omic Liquid Biopsy

22 Sep 2026

Gene Solutions will host an Industry Satellite Symposium at ESMO Congress 2026, bringing together international experts to examine how AI-enabled multi-omics and cell-free DNA analysis can move from technological innovation to evidence-based decisions that health systems can implement at scale across the cancer care continuum.  ESMO Congress 2026 will take place 23–27 October in Madrid. […]

Gene Solutions Malaysia, the National Cancer Society Malaysia (NCSM) at the National Cancer Congress Malaysia (NCCM) 2026

Gene Solutions Malaysia Advances Conversations on Earlier Cancer Detection at NCCM 2026

21 Sep 2026

Bridging gaps, building hope, and empowering lives.  Gene Solutions Malaysia was proud to partner with the National Cancer Society Malaysia (NCSM) at the National Cancer Congress Malaysia (NCCM) 2026, contributing to conversations around expanding access to earlier cancer detection across the region.  Guided by the congress theme, “Bridging Gaps, Building Hope, Empowering Lives,” our participation […]

Gene Solutions Hosts Symposium on ctDNA-Guided Breast Cancer Management at the Thai Breast Disease Society Annual Conference 2026

28 Aug 2026

Clinical perspectives and Asian real-world evidence highlight the role of multi-omic profiling and hybrid ctDNA monitoring in precision breast cancer care.  Bangkok, Thailand – 19 August 2026 – Gene Solutions Thailand hosted a dedicated symposium at the Thai Breast Disease Society (TBS) Annual Conference 2026, held from 18–21 August in Bangkok. The session, titled “ctDNA-guided management in breast cancer: from emerging evidence to clinical practice,” brought together clinical and medical […]

Vietnam’s National Hospital of Obstetrics and Gynecology Gene Solutions Gynecological cancer early detection DNA methylation

Advancing Earlier Detection of Gynecologic Cancers Through DNA Methylation

24 Aug 2026

Vietnam’s National Hospital of Obstetrics and Gynecology and Gene Solutions jointly organized a scientific symposium to discuss how DNA methylation biomarkers may support earlier detection and more precise risk stratification in gynecologic cancer care. Advances in the application of DNA methylation biomarkers were the focus of the scientific symposium, “Early Detection of Gynecologic Cancers in […]

Scientific Evidence & Global Operations

Singapore

Vietnam

Hong Kong

Philippines

India

Brazil

CAP-Accredited Laboratory

CAP-Accredited Laboratory

Indonesia

Taiwan

Malaysia

Thailand

Türkiye

USA

cfDNA tests performed
0 M+
Hospitals & Clinics Network
0 K+
NGS Labs Globally
0 +
Publications & Awarded Abstracts
0 +
CAP

CAP-Accredited Laboratories

Gene Solutions operates through a network of more than 14 company-owned and partner laboratories, supporting the delivery of precision cell-free DNA solutions across diverse markets and healthcare settings. Two Gene Solutions laboratories are individually CAP-accredited, reflecting our commitment to rigorous quality standards in next-generation sequencing.

Learn More About Our Laboratories Network

Let’s Move Precision Care Forward, Together

Whether you are exploring clinical applications, strategic partnerships, investment opportunities or a media story, connect with the right team at Gene Solutions.

Clinical Inquiries


For healthcare professionals and clinical organizations

Partnerships

For laboratories, distributors, researchers and biopharma organizations

Investor Relations

For investors and capital-market stakeholders

Media Relations

For journalists, editors and media organizations